Prof. Patrick Yu-Wai-Man
University of Cambridge / Moorfields Eye Hospital
Chair of Ophthalmology at the University of Cambridge and Honorary Consultant at Moorfields Eye Hospital. International Principal Investigator of the REFLECT Phase 3 trial for lenadogene nolparvovec (LUMEVOQ). Led the follow-up LEROS trial assessing idebenone efficacy in LHON up to five years after symptom onset. NIHR Moorfields Eye Charity Advanced Fellow. Affiliated with the MRC Mitochondrial Biology Unit and the John van Geest Centre for Brain Repair.
Research focus
Public profiles
- Institution: https://www.neuroscience.cam.ac.uk/
- Website: https://moorfieldsbrc.nihr.ac.uk/
Contact is made via official institutional channels, not private email. To request removal, email the project.
Recent publications
-
Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (REFLECT)
Journal of Clinical Investigation · 2023
-
Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy
JAMA Ophthalmology · 2025
Relevant project findings
Prof. Yu-Wai-Man is among the most active LHON clinical researchers globally. His REFLECT trial (NCT03293524) — which included Taiwan among 7 countries — established the evidence base for bilateral gene therapy efficacy. The five-year follow-up published in JAMA Ophthalmology in 2025 showed sustained visual improvement.
Contact via the University of Cambridge Department of Clinical Neurosciences or Moorfields Eye Hospital. His work is extensively documented in public peer-reviewed literature.
Project outreach status
Not yet contacted
Profile last verified: 2026-04-19